Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer (GeparSixto)

This study has been completed.
Sponsor:
Collaborators:
TEVA
Roche Pharma AG
GlaxoSmithKline
Information provided by (Responsible Party):
German Breast Group
ClinicalTrials.gov Identifier:
NCT01426880
First received: August 17, 2011
Last updated: November 21, 2013
Last verified: November 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2013
  Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)